Your browser doesn't support javascript.
loading
Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium.
Khankari, Nikhil K; Murff, Harvey J; Zeng, Chenjie; Wen, Wanqing; Eeles, Rosalind A; Easton, Douglas F; Kote-Jarai, Zsofia; Al Olama, Ali Amin; Benlloch, Sara; Muir, Kenneth; Giles, Graham G; Wiklund, Fredrik; Gronberg, Henrik; Haiman, Christopher A; Schleutker, Johanna; Nordestgaard, Børge G; Travis, Ruth C; Donovan, Jenny L; Pashayan, Nora; Khaw, Kay-Tee; Stanford, Janet L; Blot, William J; Thibodeau, Stephen N; Maier, Christiane; Kibel, Adam S; Cybulski, Cezary; Cannon-Albright, Lisa; Brenner, Hermann; Park, Jong; Kaneva, Radka; Batra, Jyotsna; Teixeira, Manuel R; Pandha, Hardev; Zheng, Wei.
Affiliation
  • Khankari NK; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37203, USA.
  • Murff HJ; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37203, USA.
  • Zeng C; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37203, USA.
  • Wen W; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37203, USA.
  • Eeles RA; The Institute of Cancer Research, 15 Cotswold Road, Sutton, London SM2 5NG, UK.
  • Easton DF; Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, UK.
  • Kote-Jarai Z; Strangeways Research Laboratory, Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, 2 Worts' Causeway, Cambridge CB1 8RN, UK.
  • Al Olama AA; The Institute of Cancer Research, 15 Cotswold Road, Sutton, London SM2 5NG, UK.
  • Benlloch S; Strangeways Research Laboratory, Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, 2 Worts' Causeway, Cambridge CB1 8RN, UK.
  • Muir K; Strangeways Research Laboratory, Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, 2 Worts' Causeway, Cambridge CB1 8RN, UK.
  • Giles GG; Institute of Population Health, University of Warwick, Coventry CV4 7AL, UK.
  • Wiklund F; Cancer Epidemiology Centre, Cancer Council Victoria, 615 St Kilda Road, Melbourne, Victoria 3004, Australia.
  • Gronberg H; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria 3010, Australia.
  • Haiman CA; Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm 171 77, Sweden.
  • Schleutker J; Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm 171 77, Sweden.
  • Nordestgaard BG; Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90089, USA.
  • Travis RC; Department of Medical Biochemistry and Genetics, University of Turku, Turku 20014, Finland.
  • Donovan JL; Institute of Biomedical Technology/BioMediTech, University of Tampere and FimLab Laboratories, Kalevantie 4, Tampere 33014, Finland.
  • Pashayan N; Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, Herlev 2730, Denmark.
  • Khaw KT; Cancer Epidemiology, Nuffield Department of Population Health University of Oxford, Oxford OX3 7LF, UK.
  • Stanford JL; School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK.
  • Blot WJ; Strangeways Research Laboratory, Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, 2 Worts' Causeway, Cambridge CB1 8RN, UK.
  • Thibodeau SN; Department of Applied Health Research, University College London, 1-19 Torrington Place, London WC1E 7HB, UK.
  • Maier C; Cambridge Institute of Public Health, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 0SR, UK.
  • Kibel AS; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
  • Cybulski C; Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA 98195, USA.
  • Cannon-Albright L; International Epidemiology Institute, 1455 Research Boulevard, Suite 550, Rockville, MD 20850, USA.
  • Brenner H; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
  • Park J; Institute of Human Genetics, University Hospital Ulm, Albert-Einstein-Allee 11, Ulm 89081, Germany.
  • Kaneva R; Department of Urology, University Hospital Ulm, Albert-Einstein-Allee 11, Ulm 89081, Germany.
  • Batra J; Division of Urology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, 45 Francis Street-ASB II-3, Boston, MA 02115, USA.
  • Teixeira MR; Washington University, 660 S. Euclid Avenue, St Louis, MO 63110, USA.
  • Pandha H; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Rybacka 1, Szczecin, Poland.
  • Zheng W; Division of Genetic Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT 84108, USA.
Br J Cancer ; 115(5): 624-31, 2016 08 23.
Article in En | MEDLINE | ID: mdl-27490808
ABSTRACT

BACKGROUND:

Prostate cancer is a common cancer worldwide with no established modifiable lifestyle factors to guide prevention. The associations between polyunsaturated fatty acids (PUFAs) and prostate cancer risk have been inconsistent. Using Mendelian randomisation, we evaluated associations between PUFAs and prostate cancer risk.

METHODS:

We used individual-level data from a consortium of 22 721 cases and 23 034 controls of European ancestry. Externally-weighted PUFA-specific polygenic risk scores (wPRSs), with explanatory variation ranging from 0.65 to 33.07%, were constructed and used to evaluate associations with prostate cancer risk per one standard deviation (s.d.) increase in genetically-predicted plasma PUFA levels using multivariable-adjusted unconditional logistic regression.

RESULTS:

No overall association was observed between the genetically-predicted PUFAs evaluated in this study and prostate cancer risk. However, risk reductions were observed for short-chain PUFAs, linoleic (ORLA=0.95, 95%CI=0.92, 0.98) and α-linolenic acids (ORALA=0.96, 95%CI=0.93, 0.98), among men <62 years; whereas increased risk was found among men ⩾62 years for LA (ORLA=1.04, 95%CI=1.01, 1.07). For long-chain PUFAs (i.e., arachidonic, eicosapentaenoic, and docosapentaenoic acids), increased risks were observed among men <62 years (ORAA=1.05, 95%CI=1.02, 1.08; OREPA=1.04, 95%CI=1.01, 1.06; ORDPA=1.05, 95%CI=1.02, 1.08).

CONCLUSION:

Results from this study suggest that circulating ω-3 and ω-6 PUFAs may have a different role in the aetiology of early- and late-onset prostate cancer.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Fatty Acids, Unsaturated Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Male Language: En Journal: Br J Cancer Year: 2016 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Fatty Acids, Unsaturated Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Male Language: En Journal: Br J Cancer Year: 2016 Type: Article Affiliation country: United States